KMTS — Kestra Medical Technologies, Ltd.

Kestra Medical Technologies (KMTS) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $28.6 million, a 66% increase year-over-year.
• Full Year Revenue: $95 million, up 59% from FY 2025.
• Gross Margin: 54.8% in Q4, up from 44.3% in the prior year; full year gross margin at 51.4%, an increase of approximately 11 percentage points.
• GAAP Net Loss: $38.8 million in Q4, improved from a loss of $51.1 million in the previous year.
• Adjusted EBITDA Loss: $26.7 million in Q4, compared to $20.3 million in the prior year.
• Cash Position: $262 million as of April 30, with a reduction in operating cash burn to $18.7 million from $24.1 million year-over-year.

2. Strategic Updates and Business Highlights

• Patient Impact: The ASSURE system provided life-saving interventions for 18,000 patients at risk of sudden cardiac arrest in FY 2026.
• Sales Growth: 6,300 prescriptions for the ASSURE system were written in Q4, with a 55% increase in new prescribers and a 65% increase in ordering facilities over the fiscal year.
• Sales Team Expansion: Increased sales territories from 80 to 130, with plans to add approximately 40 more in FY 2027.
• Market Opportunity: The wearable cardioverter defibrillator (WCD) market is projected to grow into a multibillion-dollar market, with Kestra focusing on expanding its market share.
• Innovation: Released an enhanced detection algorithm and announced a collaboration with BioBeat Technologies to improve diagnostics for hypertensive patients.

3. Forward Guidance and Outlook

• FY 2027 Revenue Guidance: Projected at $137 million, representing a 44% increase compared to FY 2026.
• Growth Drivers: Expected to come from deeper penetration in existing accounts, activation of new accounts, and improvements in revenue cycle management.
• Gross Margin Target: Management remains confident in achieving gross margins of 70%+ in the coming years.

4. Challenges and Points of Concern

• Operating Cash Burn: Although reduced, the adjusted EBITDA loss indicates ongoing financial strain as the company invests heavily in growth.
• Competitive Landscape: While Kestra is gaining market share, there are concerns about the competitive pressures from incumbents, particularly regarding their product rollouts and regulatory challenges.
• Sales Rep Ramp-Up: The effectiveness of the newly hired sales representatives remains to be seen, as they typically require a ramp-up period to reach productivity.

5. Notable Q&A Insights

• Guidance Clarification: Management emphasized that the FY 2027 revenue guidance reflects conservative estimates as they integrate new sales reps and expand market coverage.
• Market Growth vs. Share Gain: There is optimism about both market growth and share capture, with expectations of increased share gains as new territories are developed.
• Regulatory Awareness: Management is monitoring regulatory developments affecting competitors, although current issues do not directly impact Kestra's business.
• Sales Strategy: The focus is on expanding coverage in cardiology and heart failure markets, with a balanced approach to hiring and territory management.

Overall, Kestra Medical Technologies reported strong financial performance and strategic growth initiatives while navigating challenges in market competition and operational scaling. The outlook for FY 2027 remains positive, supported by a robust sales strategy and product innovation.